Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A
- PMID: 23534856
- PMCID: PMC4545639
- DOI: 10.1111/hae.12119
Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A
Abstract
Type 3 von Willebrand's disease (VWD) is a rare bleeding diathesis with complete or near complete deficiency of von Willebrand factor (VWF) and low factor VIII (FVIII) levels. In contrast, only FVIII is decreased in haemophilia A (HA). Both disorders are complicated by arthropathy. The purpose of this study was to further clarify the roles of FVIII and VWF: Antigen (VWF:Ag) in joint range of motion (ROM) loss over time. We compared joint ROM loss and other bleeding manifestations in 100 Type 3 VWD subjects (FVIII<5%) and 1814 moderate HA subjects (FVIII 1-5%) within the U.S. Universal Data Collection (UDC) database. High rates of bleeding were reported at baseline. During follow-up, moderate HA patients reported a joint (46% vs. 34%, P < 0.0001) or muscle bleed (27% vs. 16%, P < 0.0001) in a higher proportion of visits than VWD patients. Other bleeds, including mucosal, were reported in a greater proportion of visits among patients with Type 3 VWD than among those with HA (49% vs. 32%, P < 0.0001). Multivariate analysis revealed no difference in joint ROM loss over time in the Type 3 VWD vs. moderate HA populations. A higher FVIII level was protective in both VWD and HA (P < 0.001). Our findings support the hypothesis of primacy of the FVIII level in determining risk of joint haemorrhage, and may help target therapy in Type 3 VWD and moderate HA to prevent joint disability.
© 2013 John Wiley & Sons Ltd.
Conflict of interest statement
Declaration of Interests
Some of the authors have received funding from manufacturers of factor products used to treat HA and VWD. CSL Behring (consultancy: BK, research studies: BK, SLS), Baxter Healthcare (consultancy and research studies: BK, AC), Bayer Corporation (research studies: AC), Biogen-Idec (consultancy and research studies: BK).
Figures
Similar articles
-
Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.Thromb Haemost. 2018 Oct;118(10):1690-1700. doi: 10.1055/s-0038-1670704. Epub 2018 Oct 1. Thromb Haemost. 2018. PMID: 30273954
-
Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.Haemophilia. 2015 Sep;21(5):e375-83. doi: 10.1111/hae.12733. Epub 2015 Jul 24. Haemophilia. 2015. PMID: 26207643
-
Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.Blood Cells Mol Dis. 2014 Apr;52(4):181-5. doi: 10.1016/j.bcmd.2013.11.005. Epub 2013 Dec 16. Blood Cells Mol Dis. 2014. PMID: 24351655
-
Prophylaxis and von Willebrand's disease (vWD).Thromb Res. 2006;118 Suppl 1:S3-7. doi: 10.1016/j.thromres.2006.01.014. Epub 2006 Mar 31. Thromb Res. 2006. PMID: 16580053 Review.
-
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.Haematologica. 2003 Jan;88(1):94-108. Haematologica. 2003. PMID: 12551832 Review.
Cited by
-
Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status.Res Pract Thromb Haemost. 2023 Jan 13;7(2):100047. doi: 10.1016/j.rpth.2023.100047. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 36908769 Free PMC article.
-
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States.Haemophilia. 2021 May;27(3):445-453. doi: 10.1111/hae.14263. Epub 2021 Mar 29. Haemophilia. 2021. PMID: 33780098 Free PMC article.
-
[Total ankle replacement in patients with bleeding disorders].Orthopade. 2015 Aug;44(8):623-38. doi: 10.1007/s00132-015-3107-y. Orthopade. 2015. PMID: 25944517 German.
References
-
- Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103–14. - PubMed
-
- Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) Haemophilia. 2008;14:171–232. - PubMed
-
- Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006;32:555–65. - PubMed
-
- Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1236–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous

